Utility of Ethyl-Glucuronide for Evaluation of Abstinence in Patients Presenting for Liver Transplantation

Transplant Proc. 2020 Jun;52(5):1450-1452. doi: 10.1016/j.transproceed.2020.02.062. Epub 2020 May 17.

Abstract

Background: Cirrhosis as a result of alcohol-related liver disease is one of the most common indications for liver transplantation (LT) in Spain. Patients presenting for LT should be checked for alcohol abuse in clinical interviews and use of laboratory tests to confirm abstinence. The ethyl-glucuronide (EtG) test is very sensitive and can be positive in urine up to 5 days after consumption. Our main objective is to know the rate of alcohol abstinence by using the urine EtG test in patients evaluated for LT and to assess its correlation with the clinical interviews and laboratory test.

Methods: We conducted a prospective analysis of the results of the EtG in urine of patients evaluated for LT from January 2017 to March 2019 and its correlation with the medical and psychiatric interviews and with the laboratory test.

Results: We included 160 patients who were referred to LT evaluation. Among all cases, 84.1% were men, with an average age of 57.8 years. Alcohol-related liver disease was the most frequent cause (64.1%). Urine-EtG was positive in 10 patients (6.2%), 9 of them in patients with ALD and 1 in a patient with hepatitis C virus. The alcohol consumption was recognized by 80% of the patients in the clinical interview. Cases with positive EtG had higher levels of analytical parameters than those with a negative test.

Conclusions: In our series, 6.2% of patients referred for LT evaluation had recently consumed alcohol. The determination of EtG in urine is probably an effective and objective technique in the detection of alcohol consumption to ensure abstinence in the LT candidates.

MeSH terms

  • Adult
  • Alcohol Drinking / urine*
  • Biomarkers / urine
  • Enzyme-Linked Immunosorbent Assay
  • Female
  • Glucuronates / urine*
  • Humans
  • Liver Transplantation*
  • Male
  • Middle Aged
  • Patient Selection*
  • Prospective Studies
  • Spain
  • Substance Abuse Detection / methods*

Substances

  • Biomarkers
  • Glucuronates
  • ethyl glucuronide